Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

Enrolling by invitation · Phase 2

Conditions studied: Pseudohypoparathyroidism Type 1a, Obesity

In brief

The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.

Key facts

Study ID

NCT07496463

Run by

Massachusetts General Hospital

People needed

1

Starts

2026-07-21

Expected to finish

2027-04-30

Last updated by the study team

2026-07-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Known patient with PHP1a (confirmed GNAS mutation)
• Optimized therapy for diabetes and dyslipidemia

You may not qualify if…

• Use of medications that may affect endpoints that are changed within 3 months prior to Baseline or that are likely to require a change in dose during the open-label treatment period

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.